pyrvinium has been researched along with Hypoglycemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fujioka, T; Hayama, T; Nakashima, M; Nohta, H; Todoroki, K; Tomita, R; Yamaguchi, M; Yoshida, H | 1 |
| Davis, T; Ke, N; Lee, AS; Li, QX; Liu, G; Ly, M; Macdonald, J; Wong-Staal, F; Yu, DH; Zhou, D | 1 |
| Esumi, H; Kita, K; Tomitsuka, E | 1 |
3 other study(ies) available for pyrvinium and Hypoglycemia
| Article | Year |
|---|---|
Assessment of Anticancer Drug Effects on Pancreatic Cancer Cells under Glucose-Depleted Conditions Using Intracellular and Extracellular Amino Acid Metabolomics.
Topics: Amino Acids; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Blood Glucose; Cell Line, Tumor; Cell Survival; Chromatography, High Pressure Liquid; Deoxycytidine; Discriminant Analysis; Extracellular Fluid; Gemcitabine; Glucose; Humans; Hydrophobic and Hydrophilic Interactions; Hypoglycemia; Intracellular Fluid; Least-Squares Analysis; Metabolomics; Pancreatic Neoplasms; Principal Component Analysis; Pyrvinium Compounds; Reproducibility of Results; Tandem Mass Spectrometry | 2018 |
Pyrvinium targets the unfolded protein response to hypoglycemia and its anti-tumor activity is enhanced by combination therapy.
Topics: Activating Transcription Factor 4; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion; Cell Death; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Down-Regulation; Doxorubicin; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Female; Gene Expression Regulation, Neoplastic; Glucose; Glycolysis; Heat-Shock Proteins; HSP70 Heat-Shock Proteins; Humans; Hypoglycemia; Membrane Proteins; Mice; Mice, Nude; Molecular Chaperones; Protein Folding; Pyrvinium Compounds; Regulatory Factor X Transcription Factors; Transcription Factors; Transcriptional Activation; Up-Regulation; X-Box Binding Protein 1 | 2008 |
An anticancer agent, pyrvinium pamoate inhibits the NADH-fumarate reductase system--a unique mitochondrial energy metabolism in tumour microenvironments.
Topics: Animals; Anthelmintics; Antineoplastic Agents; Ascaris suum; Cattle; Cell Hypoxia; Electron Transport Complex II; Energy Metabolism; Enzyme Inhibitors; Humans; Hypoglycemia; Hypoxia; Mitochondria; Mitochondria, Heart; Oxidoreductases Acting on CH-CH Group Donors; Pyrvinium Compounds; Tumor Cells, Cultured; Tumor Microenvironment | 2012 |